A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer

• Published in: Scientific reports Vol. 12; no. 1; p. 9745
• Main Authors: Paces, Will, Ergon, Elliott, Bueche, Elizabeth, Young, G. Dave, Adisetiyo, Vitria, Luengo, Cris, James, Meredith, Caldwell, Charles, Miller, Dannah, Wambaugh, Morgan, Metcalf, Geoffrey, Gianani, Roberto
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13-06-2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114/1305; 631/67; Algorithms; Alveoli; Apoptosis; Cancer immunotherapy; Cell recognition; Humanities and Social Sciences; Image processing; Immune checkpoint; Immunofluorescence; Immunohistochemistry; Immunotherapy; Lung cancer; Lymphocytes; Macrophages; Microenvironments; multidisciplinary; Non-small cell lung carcinoma; Patients; PD-L1 protein; Science; Science (multidisciplinary); Small cell lung carcinoma
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-12697-1

PD-L1 (22C3) checkpoint inhibitor therapy represents a mainstay of modern cancer immunotherapy for non-small cell lung cancer (NSCLC). In vitro diagnostic (IVD) PD-L1 antibody staining is widely used to predict clinical intervention efficacy. However, pathologist interpretation of this assay is cumbersome and variable, resulting in poor positive predictive value concerning patient therapy response. To address this, we developed a digital assay (DA) termed Tissue Insight (TI) 22C3 NSCLC, for the quantification of PD-L1 in NSCLC tissues, including digital recognition of macrophages and lymphocytes. We completed clinical validation of this digital image analysis solution in 66 NSCLC patient samples, followed by concordance studies (comparison of PD-L1 manual and digital scores) in an additional 99 patient samples. We then combined this DA with three distinct immune cell recognition algorithms for detecting tissue macrophages, alveolar macrophages, and lymphocytes to aid in sample interpretation. Our PD-L1 (22C3) DA was successfully validated and had a scoring agreement (digital to manual) higher than the inter-pathologist scoring. Furthermore, the number of algorithm-identified immune cells showed significant correlation when compared with those identified by immunohistochemistry in serial sections stained by double immunofluorescence. Here, we demonstrated that TI 22C3 NSCLC DA yields comparable results to pathologist interpretation while eliminating the intra- and inter-pathologist variability associated with manual scoring while providing characterization of the immune microenvironment, which can aid in clinical treatment decisions.